VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug. 30, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation biocompatible passive and drug-eluting stent coatings and drug delivery technologies for the treatment of cardiovascular disease, announced today a major milestone in further expanding its intellectual property rights with the filing of two new U.S. patent applications by the University of British Columbia, a technology development partner of MIVT.

ADVERTISEMENT

The two patent applications pertain to technologies for effectively applying novel coatings onto metal medical devices to achieve desired therapeutic benefits. Both of these technologies carry considerable potential to improve the therapeutic functionality of implantable medical devices, such as metal stents.

"These latest technological leaps provide additional validation of our innovation and potential to significantly impact the biomedical marketplace," said CEO Alan Lindsay. "By continuing to expand this valuable intellectual property portfolio, we are not only effectively safeguarding our Company's commercial viability and competitive edge, but also potentially contributing to the advancement and enhancement of critical medical care. These latest patent applications are a source of great pride and gratification to our team and to the ceramic scientists at the University of British Columbia."

Significantly, these technologies build on earlier coating technologies developed by MIVT, which could have a substantial impact on the methods in which metal medical devices will be coated in the future to achieve optimal biocompatibility, safety and efficacy.

Unlike the medical coatings commonly in use today, MIVT's proprietary "HAp" coatings are based on a substance that is already naturally found in the human body known as hydroxyapatite. MIVT's innovative coating technologies are designed to inhibit adverse reactions of the immune system.

MIV Therapeutics is committed to providing improved solutions for the treatment of cardiovascular disease and other conditions. In collaboration with the University of British Columbia, MIVT is focused on developing proprietary HAp coating formulations to protect surrounding tissue from chemical interaction with bare-metal stents, an interaction which typically causes an aggressive immune response, resulting in restenosis, or re-narrowing of arteries, and a risk of thrombus in the stented artery.

MIVT's novel coatings are based upon a natural material, Hydroxyapatite, a component of hard tissue found in human teeth and bone, which enables the surface of metallic stents to virtually mimic the natural state of structurally-sound 100% biocompatible and bio-active tissue.

The Company believes its technology also has potential for an array of additional medical applications, including dental, hip and bone repair implants.

About MIV Therapeutics, Inc.

MIV Therapeutics, Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and superior healing properties pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug eluting technologies based on Hydroxyapatite provide attractive alternative solution to polymer-based drug eluting coatings currently in the stent market. The Company's drug eluting coating is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug-eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit: http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

---

Contact:

     MIV Therapeutics Inc.
     Investor Relations, 604-301-9545
     Toll-free: 800-221-5108
     Fax: 604-301-9546
     E-mail: investor@mivtherapeutics.com
     Web: www.mivtherapeutics.com
     Or for Product Inquiries and Business Opportunities:
     Arc Rajtar, 604-301-9545 Ext. 22
     arajtar@mivi.ca
     or
     Trilogy Capital Partners
     Paul Karon, Toll-free: 800-342-1467
     paul@trilogy-capital.com